Inhibitory effects of topical cyclosporine A 0.05% on immune-mediated corneal neovascularization in rabbits.
BACKGROUND
We aimed to study the inhibitory effects of topical cyclosporine A (CsA) 0.05% on immune-mediated corneal neovascularization, and to compare its efficacy with those of dexamethasone 0.1% and bevacizumab 0.5%.


METHODS
Immune-mediated corneal neovascularization was created in 36 right eyes of 36 rabbits. The rabbits were then randomized into four groups. Group I received CsA 0.05%, Group II received dexamethasone 0.1%, Group III received bevacizumab 0.5%, and Group IV received isotonic saline twice a day for 14 days. The corneal surface covered with neovascular vessels was measured on the photographs. The rabbits were then sacrificed and the corneas excised. Paraffin-embedded sections were stained with hematoxylin-eosin and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling assay.


RESULTS
The means of percent area of corneal neovascularization in Group I, II, III, and IV were 24.4%, 5.9%, 37.1%, and 44.1%, respectively. The inhibitory effect of CsA 0.05% was found to be better than the effect found in the bevacizumab 0.5% and control groups (p = 0.03 and p = 0.02, respectively). CsA 0.05% was found to have significantly lesser inhibitory effects on corneal neovascularization than dexamethasone 0.1% (p < 0.001). Apoptotic cell density was higher in Group III and Group IV than in Group I and Group II. There was no difference between Group I and Group II in terms of apoptotic cell density (p = 0.7).


CONCLUSIONS
Topical CsA 0.05% was shown to have an inhibitory effect on immune-mediated corneal neovascularization in rabbits.
Ophthalmology Clinic, Izzet Baysal State Hospital, Bolu, Turkey.
Yasin Yücel
YY
Bucak
Mesut
M
Erdurmus
Elçin Hakan
EH
Terzi
Aysel
A
Kükner
Serdal
S
Çelebi
D000287:Administration, Topical; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D017209:Apoptosis; D001183:Arthus Reaction / Q000188:drug therapy / Q000276:immunology; D000068258:Bevacizumab; D001710:Biotin / Q000031:analogs & derivatives; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000276:immunology; D016572:Cyclosporine / Q000008:administration & dosage*; D003856:Deoxyuracil Nucleotides; D003907:Dexamethasone / Q000008:administration & dosage; D004195:Disease Models, Animal; D005938:Glucocorticoids / Q000008:administration & dosage; D007124:Immunoenzyme Techniques; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D020287:In Situ Nick-End Labeling; D009883:Ophthalmic Solutions; D011817:Rabbits; D012710:Serum Albumin, Bovine / Q000276:immunology
C483775:5-(3-(1-(5-(5-(biotinylamino)pentanamidomethyl)-2-nitrophenyl)ethoxycarbonylamino)propenyl)-2'-deoxyuracil 5'-triphosphate; D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D003856:Deoxyuracil Nucleotides; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D009883:Ophthalmic Solutions; D012710:Serum Albumin, Bovine; D000068258:Bevacizumab; D001710:Biotin; D003907:Dexamethasone; D016572:Cyclosporine